SEC Form 4 · accession 0001140361-16-047337
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy Hoey
Officer — SVP, Cancer Biology
Period of report
Jan 6, 2016
Accepted (ET)
Jan 8, 2016 · 7:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jan 6, 2016 | S | 2,092 | $22.3006 | D | 47,251 | D | |
| Common StockF2 | Jan 6, 2016 | S | 69 | $21.5601 | D | 47,182 | D | |
| Common StockF2 | Jan 7, 2016 | S | 1 | $21.33 | D | 47,181 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes.
- F2Includes 15,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.